Introduction
============

Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer-associated mortality worldwide according to the global cancer statistics from 2018 ([@b1-ol-0-0-11203]). In the United States, approximately 135,430 new cases are diagnosed each year and approximately 50,260 patients die of CRC, which accounts for approximately 9% of all cancer-associated mortalities ([@b2-ol-0-0-11203]). In 2015, CRC was considered as the fifth most common type of cancer in terms of occurrence and mortality in China ([@b3-ol-0-0-11203]). Cancer stage is a major factor contributing to the overall survival of patients with CRC. The 3-year survival rate is 80--90% for patients with CRC who are diagnosed with stages I or II, whereas the 3-year survival rate is reduced to 20% for patients with CRC diagnosed with stage IV ([@b4-ol-0-0-11203]).

Over the past decade, large-scale sequencing studies have investigated the genetic basis of CRC and uncovered key pathways involved in the pathogenesis of CRC, including WNT, RAS-MAPK, PI3K, TGF-β, P53 and DNA mismatch repair pathways ([@b5-ol-0-0-11203]--[@b8-ol-0-0-11203]). The Cancer Genome Atlas program conducted a genome-scale analysis of 276 CRC samples using multi-omics sequencing results and discovered that 16% of hypermutated CRC samples are characterized by high microsatellite instability, hypermethylation, mutL homolog 1 (*MLH1*) silencing or somatic mutations in mismatch repair genes and polymerases. In addition to the known mutations in the genes APC regulator of WNT signaling pathway (*APC*), tumor protein 53 (*TP53*), SMAD family member 4 (*SMAD4*), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha and KRAS proto-oncogene GTPase, 19 new recurrently mutated genes have been detected, including AT-rich interaction domain 1A (*ARID1A*), SRY-box transcription factor 9 (*SOX9*) and APC membrane recruitment protein 1, and amplifications of the genes erb-b2 receptor tyrosine kinase 2 and insulin like growth factor 2 have been identified ([@b9-ol-0-0-11203]).

Although our understanding of genomic alterations of oncology has rapidly improved ([@b5-ol-0-0-11203]--[@b9-ol-0-0-11203]), the uncommonly mutated genes in CRC, especially in the Asian population, remain unknown. In the present study, targeted region sequencing (508 genes) on 22 CRC and 10 paired non-cancerous samples from patients with CRC was performed to study genetic changes. The conclusion of this study may provide further insight into genomic changes in CRC and determine potential therapeutic targets in CRC.

Materials and methods
=====================

### Patients and samples

A total of 22 primary CRC and 10 paired normal colorectal tissues were surgically resected at Sanming Hospital between May 2014 and August 2015 and immediately frozen. Patients with secondary CRC were excluded from the present study. The mean age of patients at diagnosis was 66.7±10.3 years and ranged between 35 and 80 years old. Written informed consent was obtained from all patients and the study was approved by the Ethics Review Board of the Sanming First Hospital. The clinical characteristics of patients are presented in [Table I](#tI-ol-0-0-11203){ref-type="table"}.

### DNA extraction, library preparation and sequencing

Genomic DNA was extracted from the 22 CRC and 10 paired normal colorectal tissues using the QIAamp DNA Blood Midi Kit (Qiagen GmbH) according to the manufacturer\'s protocol. A NanoDrop 2000 (NanoDrop Technologies; Thermo Fisher Scientific, Inc.) was used to assess DNA quality and concentration. Total DNA samples (400 ng) were used to construct sequencing libraries following the improved protocols for Illumina sequencing ([@b10-ol-0-0-11203]). In brief, genomic DNA samples were fragmented and ligated with Illumina standard adapters to both fragments ends. Adapter-ligated fragments are then PCR-amplified and gel-purified. Libraries were pooled ([@b11-ol-0-0-11203]) and hybridized using the Oseq-T panel (508 genes; BGI Genomics Co. Ltd.) for capturing. The process of hybridization was performed as previously described ([@b12-ol-0-0-11203]). The hybridized product was sequenced using the Illumina MiSeq platform (Illumina, Inc.) using a 100 paired-end (PE) sequencing strategy.

### Variant calling and filtering

High-quality reads were aligned to the human reference genome 19 (<http://hgdownload.soe.ucsc.edu/goldenPath/hg19/chromosomes/>) using MEM algorithms of Burrows-Wheeler-Aligner v.0.7.17 (<http://bio-bwa.sourceforge.net>) with default parameters, except that the number of threads was set to 2 to accelerate this mapping process (-t 2) ([@b13-ol-0-0-11203]). Read deduplication was performed utilizing Picard v.1.98 software (<http://picard.sourceforge.net/>), using the main parameters as follows: ASSUME_SORTED=true and VALIDATION_STRINGENCY=LENIENT. Local realignment around insertion-deletions were performed using GATK v3.3.0 RealignerTargetCreator and IndelRealigner model (<https://software.broadinstitute.org/gatk/>) ([@b14-ol-0-0-11203]). Base quality score recalibration was also performed by GATK v3.3.0 BaseRecalibrator and PrintReads model (<https://software.broadinstitute.org/gatk/>) ([@b13-ol-0-0-11203]). Single nucleotide variant and insertion-deletion (indel) mutations were detected by 3.3.0 HaplotypeCaller of GATK (<https://software.broadinstitute.org/gatk/>). New variants and variants with maximum allele frequency \<1% reported in the 1000 genome project ([@b15-ol-0-0-11203]) and dbsnp v141 database ([@b16-ol-0-0-11203]) were considered as high confidence variants. High confidence variants that were detected specifically in CRC samples but not in normal colon tissues were regarded as somatic mutations. The SnpEff tool (<http://snpeff.sourceforge.net/SnpEff_manual.html>) was applied to annotate somatic mutations ([@b17-ol-0-0-11203]). The final somatic variants and annotation results were used in the downstream analysis.

### Driver gene prediction and functional annotation

Driver genes were predicted using three distinct computational tools, including MutSigCV (v1.0) (<https://cloud.genepattern.org/gp/pages/index.jsf>) ([@b18-ol-0-0-11203]), oncodriveFM (v0.0.1) (<https://www.intogen.org>) ([@b19-ol-0-0-11203]) and Integrated CAncer GEnome Score (iCAGES) (<http://icages.wglab.org>) ([@b20-ol-0-0-11203]). All parameters were set to default values. Driver genes were determined according to the following criteria: i) Genes with q-value \<0.1 in the MutSigCV analysis ([@b21-ol-0-0-11203]); ii) genes with q-value less \<0.05 in the oncodriveFM analysis ([@b19-ol-0-0-11203]); and iii) genes predicted to be drivers by iCAGES, with icagesGeneScores of predicted drivers \>0.5 ([@b22-ol-0-0-11203]). To functionally annotate these driver genes, the Database for Annotation, Visualization and Integrated Discovery (<https://david.ncifcrf.gov>) ([@b23-ol-0-0-11203]) was applied to analyse the significant Gene Ontology (GO; <http://david.ncifcrf.gov>) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://david.ncifcrf.gov>) ([@b24-ol-0-0-11203]) pathways in which driver genes were enriched. Bonferroni adjusted P-value \<0.05 indicated a statistical significance.

### Copy number variation analysis

Focal copy number variations (CNVs) were detected using CONTRA v2.0.8 software ([@b25-ol-0-0-11203]) between CRC and paired normal samples using default parameters, (eg: contra.py -t \*.bed -s \*tumor.bam -c \*normal.bam -f hg19.fasta -o output-removeDups), except for '-removeDups'. For CRC samples without paired normal tissues, deduplicated bam files of 10 normal samples were merged to form one bam file. Focal CNVs were detected between deduplicated bam files of CRC samples and the merged bam file of 10 normal samples. All parameters were set to default values. Focal CNVs with P-values \<0.05 were considered statistically significant. Fraction of CNV (FCNV) was computed as follows: FCNV=(size of significant CNVs)/size of exons.

### Statistical analyses

In the MutSigCV analysis, P-value was calculated for the gene by convoluting the background distributions of all the mutation types, and determining the probability of meeting or exceeding that score by background mutation alone. Benjamini-Hochberg false discovery rate procedure was used to correct for P-values of multiple tests. In the oncodrive FM analysis, the method randomly sampled one milliongroups of the same number of observed mutations. P-value referred to the fraction of functional impact scores equal to or greater than the observed average functional impact score of the gene. Bonferroni correction was applied to calculate the q-value for each gene. The Bonferroni correction was used to adjust the P-values computed by Fisher\'s exact test in the GO and KEGG pathway enrichment analyses. Difference of quantitative values was compared between two groups using Wilcoxon rank-sum test in R 3.2.0 ([www.r-project.org](www.r-project.org)).

Results
=======

### Clinical and demographic characteristics of the 22 patients with CRC

The 22 patients with CRC comprised 13 female and 9 male patients. The primary sites of CRC included rectum (7 cases), sigmoideum (1 case), ascending colon (7 cases), transverse colon (1 case), rectosigmoid (1 case) and descending colon (5 cases). The pathological types of the 22 patients comprised 14 cases of protruding adenocarcinoma, 7 cases of protruding and mucinous adenocarcinoma and 1 case of protruding moderately differentiated adenocarcinoma. In addition, 6, 11, 3 and 2 patients with CRC were diagnosed with stages I, II, III and IV, respectively. Furthermore, 2 and 4 patients presented positive metastasis in lymph nodes and distant organs, respectively ([Table I](#tI-ol-0-0-11203){ref-type="table"}).

### Summary statistics of alignment to target regions

A 3.65 Mb target region comprising 508 genes was captured from genomic DNA and used to perform variant calling. On average, 98.87% reads were mapped successfully. The duplicated reads were removed, resulting in an average of 4,312,287 (425.73 Mb) effective reads. Of the total effective bases, 69.95% was mapped to target regions (capture specificity), and the mean sequencing depth in the target regions was 81.57-fold. On average, 99.37% of targeted bases had at least 1× coverage, and 97.15% of the targeted bases had at least 10× coverage ([Table SI](#SD1-ol-0-0-11203){ref-type="supplementary-material"}). In addition, the distributions of per-base sequencing depth, cumulative sequencing depth and insert size are presented in [Fig. 1](#f1-ol-0-0-11203){ref-type="fig"}. The density of sequencing depth on the target region followed normal distribution, with a mean of 100X. As expected, the peak of the insertion size distribution of the sequencing library was \~200 bp.

### Somatic mutations in colorectal cancer

To characterize the mutational spectrum, a targeted region sequencing (3.65 Mb) on the 22 CRC and 10 paired normal tissues was performed. A total of 1,335 somatic mutations were identified, including 122 missense mutations, 48 silent variants, 48 splicing site variants, 13 inframe deletions and 8 inframe insertions. Furthermore, 513, 404 and 113 variants were located in the untranslated region, intron and noncoding regions, respectively. In total, 52 variants caused a frame shift and 15 variants led to stop gain ([Fig. 2A](#f2-ol-0-0-11203){ref-type="fig"}). The somatic mutation rates varied considerably among the samples. The average mutation density was 16.63 mutations/Mb in the 508-gene panel (range, 4.38--69.04 mutations/Mb). To analyse the cause for the different mutation densities, the mutation statuses in DNA mismatch repair (MMR) pathway genes was assessed, including *MLH1, MLH3*, mutS homolog 2 (*MSH2*), *MSH3, MSH6* and PMS1 homolog 2. Five patients with CRC had mutations in any of the MMR genes, and the average mutation density in MMR mutant patients was significantly higher compared with MMR wild-type patients (31.73 vs. 12.18 mutations/Mb; P=0.01; Wilcoxon rank sum test; [Fig. 2B](#f2-ol-0-0-11203){ref-type="fig"}). In addition, indels, C\>T/G\>A and A\>G/T\>C were the three most prevalent mutation types with mutation rates of 48, 18. 8, and 12.8%, respectively ([Fig. 2C](#f2-ol-0-0-11203){ref-type="fig"}).

### Driver genes in colorectal cancer

MutSigCV analysis identified four recurrently mutated genes, named *APC, TP53*, SUZ12 polycomb repressive complex 2 subunit (*SUZ12*) and AT-rich interaction domain 5B (*ARID5B*), with significant statistical evidence (q-value \<0.2). Furthermore, OncodriveFM and iCAGES detected five and 24 driver genes, respectively. In total, 29 unique driver genes were detected using these three computational tools. *TP53* was the overlapping gene among the three sets of driver genes. *APC, SMAD4*, neurofibromin 1 (*NF1*), *ARID5B and* nuclear receptor corepressor 1 (*NCOR1)* were the top five most frequently mutated genes in patients with CRC with mutation rates of 68, 36, 36, 32 and 27%, respectively ([Fig. 3](#f3-ol-0-0-11203){ref-type="fig"}). In addition, the tumour-suppressor genes *APC* and *SMAD4* had an excessively high number of frameshift or nonsense mutations. The average mutation rate was 18% in the 29 driver genes ([Table SII](#SD1-ol-0-0-11203){ref-type="supplementary-material"}). Certain driver genes, including mitogen-activated protein kinase kinase kinase 1 (*MAP3K1*), *FGFR4* and *PDGFR-β*, were mutated at low frequencies (5% for all three genes), and firstly reported as driver genes in CRC samples.

To functionally annotate the 29 driver genes, GO term and KEGG pathway enrichment analyses were performed. The results from GO enrichment analysis demonstrated that the 29 driver genes were significantly enriched in 152 GO terms, including 'positive regulation of cell proliferation', 'phosphatidylinositol-mediated signalling', 'cellular response to DNA damage stimulus' and 'MAPK cascade' (Bonferroni-adjusted P\<0.05; data not shown). Furthermore, the driver genes were significantly enriched in 9 KEGG pathways, including 'Wnt signalling pathways', 'cell cycle', 'colorectal cancer', 'melanoma, glioma', 'pancreatic and endometrial cancer' (Bonferroni-adjusted P\<0.05; [Table SIII](#SD1-ol-0-0-11203){ref-type="supplementary-material"}).

### Copy number variation analysis in CRC samples

To further analyse the copy number variation in driver genes, CONTRA was used to detect focal CNVs at the exon level. The results demonstrated that 12 driver genes had FCNV \>20% in all CRC sample, including *GNAS* complex locus (*GNAS*), BRCA2 DNA repair associated (*BRCA2*), *SOX9*, fibroblast growth factor receptor 4 (*FGFR4*), *SMAD4, SUZ12, FGFR3*, epidermal growth factor receptor (*EGFR*), E1A binding protein p300, *NCOR1, TP53* and insulin like growth factor 1 receptor. In particular, *GNAS* presented a significant focal gain \>20% in 45% (10/22) of CRC samples compared with normal samples. In addition, tumour suppressor genes, including *TP53*, presented a significant focal loss \>20% in 22.7 (5/22) and 4.5% (1/22) of CRC samples compared with normal samples. The *EGFR* oncogene exhibited a significant focal gain \>20% in 9.1% (2/22) of CRC samples compared with normal samples ([Table II](#tII-ol-0-0-11203){ref-type="table"}).

Discussion
==========

The activation of driver mutations might serve a crucial role in cancer development ([@b26-ol-0-0-11203]). Genes that carry these driver mutations are considered as driver genes and are essential to tumorigenesis ([@b27-ol-0-0-11203]--[@b31-ol-0-0-11203]). The most common approach to predict driver genes in numerous cancer samples is the identification of genes that present significantly higher mutation frequencies compared with the background mutation rate ([@b18-ol-0-0-11203],[@b32-ol-0-0-11203]), via the MutSigCV model for example. However, many driver genes may occur at a low frequency. (\<1%) in tumours ([@b8-ol-0-0-11203]). Novel computational tools have therefore been developed to detect driver genes with middle or low mutation frequencies. OncodriveFM first evaluates the functional impact of a somatic mutation using the three different tools SIFT ([@b33-ol-0-0-11203]), PolyPhen2 ([@b34-ol-0-0-11203]) and MutationAssessor ([@b35-ol-0-0-11203]), and applies the transFIC method (<http://bg.upf.edu/transfic>) to transform the three functional scores into a uniform score ([@b36-ol-0-0-11203]). To identify driver genes, oncodriveFM ([@b19-ol-0-0-11203]) compares the actual functional impact with a null distribution model generated by 1,000,000 permutations and computes the bias towards the accumulation of variants with high functional impact.

The iCAGES is a novel statistical framework that can predict driver variants by integrating contributions from coding, noncoding and structural variants. iCAGES can therefore identify driver genes by combining genomic information and biological knowledge to generate prioritized drug treatments ([@b20-ol-0-0-11203]). iCAGES consists of three consecutive layers. The first layer prioritizes personalized cancer driver coding, noncoding and structural variations. The second layer associates these mutations to genes using a statistical model with prior biological knowledge of cancer driver genes for specific subtypes of cancer. The third layer generates a list of drugs targeting the repertoire of these potential driver genes. Three computational tools, including MutSigCV, oncodriveFM and iCAGES, were applied to detect driver genes based on complementary principles independently of somatic mutation recurrence. The combination of the three tools enables the detection of recurrently and rarely mutated driver genes in a more comprehensive manner than with MutSigCV alone ([@b9-ol-0-0-11203]).

Over the last decade, large-scale sequencing projects have been completed to characterize the mutation profiling of CRC ([@b9-ol-0-0-11203],[@b37-ol-0-0-11203],[@b38-ol-0-0-11203]). Recurrent gene mutations, including *APC*, KRAS proto-oncogene, GTPase and titin genes, and dysregulated signalling pathways, including the Wnt, tumour growth factor-β, phosphoinositide 3-kinase and P53 signalling pathways, have been reported to contribute to CRC carcinogenesis ([@b9-ol-0-0-11203],[@b37-ol-0-0-11203],[@b38-ol-0-0-11203]). Giannakis *et al* ([@b37-ol-0-0-11203]) identified recurrently mutated genes in CRC, including BCL9 like, RNA binding motif protein 10, CCCTC-binding factor and Kruppel like factor 5, which were not previously reported in CRC. R-spondin (RSPO) gene fusions are present in 10% of colon tumours and are mutually exclusive with *APC* mutations, which suggests that they might be involved in the activation of Wnt signalling pathway ([@b38-ol-0-0-11203]). In the present study, the use of three computational algorithms, including MutSigCV, oncodriveFM and iCAGES allowed the detection of 29 driver genes on 22 CRC samples using somatic mutations. The results demonstrated that *APC, SMAD4, NF1, ARID5B and TP53* genes were frequently mutated in patients with CRC, which was similar to results from a previous study ([@b9-ol-0-0-11203]). Among the 29 driver genes, *EGFR*, kinase insert domain receptor and platelet derived growth factor receptor beta (*PDGFR-β*) are oncogenes, whereas von Hippel-Lindau tumor suppressor, *NF1, SUZ12, BRCA1* and *BRCA2* are tumour suppressor genes, according to the curated oncogene ([@b39-ol-0-0-11203]) and tumour suppressor gene ([@b40-ol-0-0-11203]) databases. In particular, certain driver genes, including mitogen-activated protein kinase kinase kinase 1 (*MAP3K1*), *FGFR4* and *PDGFR-β*, had low mutation frequencies. To the best of our knowledge, these three genes were reported as driver genes in CRC samples for the first time. *MAP3K1* is a Ser/Thr protein kinase that belongs to the mitogen-activated protein kinase kinase kinase 1 (MEKK)/serine/threonine protein kinase subgroup of the MEKK family. Silencing MAP3K1 expression significantly enhances paclitaxel-induced cell proliferation inhibition in breast cancer cells, ([@b41-ol-0-0-11203]) pancreatic cancer cells ([@b42-ol-0-0-11203]) and medulloblastoma cells ([@b43-ol-0-0-11203]) and inhibits the human pancreatic cancer cell invasive and migratory abilities ([@b43-ol-0-0-11203]). In accordance to previous studies ([@b41-ol-0-0-11203]--[@b44-ol-0-0-11203]), this study suggests that *MAP3K1* may have oncogenic role in cancers. It has been demonstrated that *FGFR4* serves the role of oncogene and regulator of drug or radiation resistance in CRC ([@b45-ol-0-0-11203]). Furthermore, *FGFR4* silencing can inhibit colon cancer cell line proliferation and induces caspase-dependent apoptosis ([@b45-ol-0-0-11203]). In addition, *FGFR4* can regulate FLICE-like inhibitory protein expression via *Signal transducer and activator of transcription 3*, conferring resistance to 5-fluorouracil (5-FU) and oxaliplatin chemotherapy in colon cancer cell lines ([@b45-ol-0-0-11203]). Furthermore, it has been reported that *FGFR* induces resistance to radiation therapy in CRC by downregulating *RAD51 recombinase* level and inhibiting cancer cell proliferation ([@b46-ol-0-0-11203]). *PDGFR-β* is a cell surface tyrosine kinase receptor for members of the PDGF family ([@b47-ol-0-0-11203]). It has been demonstrated that *PDGFR-β* high expression is positively correlated with lymphatic metastasis and advanced UICC stages, and that *PDGFR-β* high expression might be considered as a negative factor for the prognosis of patients with colon cancer ([@b48-ol-0-0-11203]--[@b50-ol-0-0-11203]). Decreased expression of PDGFR-β can inhibit the invasion and proliferation of CRC cell lines (HCT116 and DLD-1) in a dose-dependent manner ([@b48-ol-0-0-11203]). PDGFR-β expression may therefore be considered as a risk factor for recurrence in CRC, suggesting that PDGFR inhibitor could represent a useful therapeutic agent for CRC ([@b48-ol-0-0-11203]). These newly identified driver genes may be considered as novel candidates that could be used for functional validation in future investigation.

In conclusion, the present study screened over 500 genes in order to analyse the genetic alterations present in 22 CRC samples. A total of 29 driver genes were identified. Driver genes with significant copy number variations, such as *GNAS* and *TP53*, may be crucial in CRC oncogenesis. These findings discoveries may serve as basis for further investigation on CRC diagnosis and oncogenesis.
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###### 

Clinical and demographic characteristics of the 22 patients with CRC.

  Variable                                                CRC (n=22)
  ------------------------------------------------------- ------------
  Sex                                                     
    Male                                                  9
    Female                                                13
  Tumor/adenoma/Polyp location                            
    Rectum                                                7
    Sigmoideum                                            1
    Ascending colon                                       7
    Transverse colon                                      1
    Rectosigmoid                                          1
    Descending colon                                      5
  Pathologic diagnosis                                    
    Protruding adenocarcinoma                             14
    Protruding and mucinous adenocarcinoma                7
    Protruding moderately differentiated adenocarcinoma   1
  Pathologic stage                                        
    I                                                     6
    II                                                    11
    III                                                   3
    IV                                                    2
  Tumor stage                                             
    T1                                                    6
    T2                                                    12
    T3                                                    2
    T4                                                    2
  Nodal stage                                             
    N0                                                    18
    N1                                                    1
    N2                                                    3
  Metastasis stage                                        
    M0                                                    20
    M1                                                    2

###### 

Fraction of significant CNVs of driver genes in colorectal cancer samples.

  Genes     Sample   Fraction of CNV   CNV type
  --------- -------- ----------------- ----------
  *GNAS*    13CB     0.54              Gain
  *GNAS*    15CB     0.55              Gain
  *GNAS*    16CB     0.86              Gain
  *GNAS*    18CB     0.56              Gain
  *GNAS*    19CB     0.56              Gain
  *GNAS*    20CB     0.23              Gain
  *GNAS*    21CB     0.65              Gain
  *GNAS*    31CB     0.33              Gain
  *GNAS*    36CB     0.56              Gain
  *GNAS*    41CB     0.93              Gain
  *BRCA2*   17CB     0.58              Gain
  *BRCA2*   28CB     0.88              Gain
  *BRCA2*   30CB     0.56              Gain
  *BRCA2*   32CB     0.49              Loss
  *BRCA2*   35CB     0.48              Loss
  *SMAD4*   19CB     0.31              Loss
  *SMAD4*   30CB     0.27              Loss
  *SMAD4*   31CB     0.22              Loss
  *SMAD4*   40CD     0.22              Loss
  *SOX9*    17CB     0.29              Loss
  *SOX9*    18CB     0.83              Gain
  *SUZ12*   19CB     0.23              Loss
  *SUZ12*   30CB     0.22              Gain
  *FGFR3*   11CB     0.20              Gain
  *FGFR3*   18CB     0.22              Gain
  *EGFR*    16CB     0.73              Gain
  *EGFR*    31CB     0.33              Gain
  *EP300*   16CB     0.42              Gain
  *NCOR1*   19CB     0.23              Loss
  *TP53*    39CB     0.27              Loss
  *IGF1R*   42CB     0.25              Loss
  *FGFR4*   19CB     0.20              Gain

*BRCA2*, BRCA2 DNA repair associated; CNV, copy number variation; *EGFR*, epidermal growth factor receptor; *EP300*, E1A binding protein p300; *FGFR3*, fibroblast growth factor receptor 3; *FGFR4*, fibroblast growth factor receptor 4; *GNAS*, GNAS complex locus; *IGF1R*, insulin like growth factor 1 receptor; *NCOR1*, nuclear receptor corepressor 1; *SMAD4*, SMAD family member 4; *SOX9*, SRY-box transcription factor 9; *SUZ12*, SUZ12 polycomb repressive complex 2 subunit; *TP53*, tumor protein p53.
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